HER2 MUTATION INHIBITORS
This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such com...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ELLIS, BRYAN DANIEL ROSEN, RACHEL ZOE NEWHOUSE, BRADLEY JON SHELP, RUSSELL ANDREW PAJK, SPENCER PHILLIP LAIRD, ELLEN RUTH HICKEN, ERIK JAMES LAZZARA, NICHOLAS CHARLES |
| description | This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
La présente invention concerne des composés de formule (I) : (I), et des énantiomères de ceux-ci, et des sels pharmaceutiquement acceptables de formule (I) et lesdits énantiomères, formule dans laquelle A, L2, R1, R2, R3, R4 et n sont tels que définis dans la description. L'invention concerne en outre des compositions pharmaceutiques comprenant de tels composés et sels, et des procédés et des utilisations de ces composés, sels et compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer, chez un sujet qui le nécessite. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3225045A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3225045A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3225045A13</originalsourceid><addsrcrecordid>eNrjZJDwcA0yUvANDXEM8fT3U_D08_B08gzxDwrmYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxzo7GRkamBiamjobGRCgBALTLHyw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HER2 MUTATION INHIBITORS</title><source>esp@cenet</source><creator>ELLIS, BRYAN DANIEL ; ROSEN, RACHEL ZOE ; NEWHOUSE, BRADLEY JON ; SHELP, RUSSELL ANDREW ; PAJK, SPENCER PHILLIP ; LAIRD, ELLEN RUTH ; HICKEN, ERIK JAMES ; LAZZARA, NICHOLAS CHARLES</creator><creatorcontrib>ELLIS, BRYAN DANIEL ; ROSEN, RACHEL ZOE ; NEWHOUSE, BRADLEY JON ; SHELP, RUSSELL ANDREW ; PAJK, SPENCER PHILLIP ; LAIRD, ELLEN RUTH ; HICKEN, ERIK JAMES ; LAZZARA, NICHOLAS CHARLES</creatorcontrib><description>This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
La présente invention concerne des composés de formule (I) : (I), et des énantiomères de ceux-ci, et des sels pharmaceutiquement acceptables de formule (I) et lesdits énantiomères, formule dans laquelle A, L2, R1, R2, R3, R4 et n sont tels que définis dans la description. L'invention concerne en outre des compositions pharmaceutiques comprenant de tels composés et sels, et des procédés et des utilisations de ces composés, sels et compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer, chez un sujet qui le nécessite.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221229&DB=EPODOC&CC=CA&NR=3225045A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221229&DB=EPODOC&CC=CA&NR=3225045A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ELLIS, BRYAN DANIEL</creatorcontrib><creatorcontrib>ROSEN, RACHEL ZOE</creatorcontrib><creatorcontrib>NEWHOUSE, BRADLEY JON</creatorcontrib><creatorcontrib>SHELP, RUSSELL ANDREW</creatorcontrib><creatorcontrib>PAJK, SPENCER PHILLIP</creatorcontrib><creatorcontrib>LAIRD, ELLEN RUTH</creatorcontrib><creatorcontrib>HICKEN, ERIK JAMES</creatorcontrib><creatorcontrib>LAZZARA, NICHOLAS CHARLES</creatorcontrib><title>HER2 MUTATION INHIBITORS</title><description>This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
La présente invention concerne des composés de formule (I) : (I), et des énantiomères de ceux-ci, et des sels pharmaceutiquement acceptables de formule (I) et lesdits énantiomères, formule dans laquelle A, L2, R1, R2, R3, R4 et n sont tels que définis dans la description. L'invention concerne en outre des compositions pharmaceutiques comprenant de tels composés et sels, et des procédés et des utilisations de ces composés, sels et compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer, chez un sujet qui le nécessite.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJDwcA0yUvANDXEM8fT3U_D08_B08gzxDwrmYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxzo7GRkamBiamjobGRCgBALTLHyw</recordid><startdate>20221229</startdate><enddate>20221229</enddate><creator>ELLIS, BRYAN DANIEL</creator><creator>ROSEN, RACHEL ZOE</creator><creator>NEWHOUSE, BRADLEY JON</creator><creator>SHELP, RUSSELL ANDREW</creator><creator>PAJK, SPENCER PHILLIP</creator><creator>LAIRD, ELLEN RUTH</creator><creator>HICKEN, ERIK JAMES</creator><creator>LAZZARA, NICHOLAS CHARLES</creator><scope>EVB</scope></search><sort><creationdate>20221229</creationdate><title>HER2 MUTATION INHIBITORS</title><author>ELLIS, BRYAN DANIEL ; ROSEN, RACHEL ZOE ; NEWHOUSE, BRADLEY JON ; SHELP, RUSSELL ANDREW ; PAJK, SPENCER PHILLIP ; LAIRD, ELLEN RUTH ; HICKEN, ERIK JAMES ; LAZZARA, NICHOLAS CHARLES</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3225045A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ELLIS, BRYAN DANIEL</creatorcontrib><creatorcontrib>ROSEN, RACHEL ZOE</creatorcontrib><creatorcontrib>NEWHOUSE, BRADLEY JON</creatorcontrib><creatorcontrib>SHELP, RUSSELL ANDREW</creatorcontrib><creatorcontrib>PAJK, SPENCER PHILLIP</creatorcontrib><creatorcontrib>LAIRD, ELLEN RUTH</creatorcontrib><creatorcontrib>HICKEN, ERIK JAMES</creatorcontrib><creatorcontrib>LAZZARA, NICHOLAS CHARLES</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ELLIS, BRYAN DANIEL</au><au>ROSEN, RACHEL ZOE</au><au>NEWHOUSE, BRADLEY JON</au><au>SHELP, RUSSELL ANDREW</au><au>PAJK, SPENCER PHILLIP</au><au>LAIRD, ELLEN RUTH</au><au>HICKEN, ERIK JAMES</au><au>LAZZARA, NICHOLAS CHARLES</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HER2 MUTATION INHIBITORS</title><date>2022-12-29</date><risdate>2022</risdate><abstract>This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
La présente invention concerne des composés de formule (I) : (I), et des énantiomères de ceux-ci, et des sels pharmaceutiquement acceptables de formule (I) et lesdits énantiomères, formule dans laquelle A, L2, R1, R2, R3, R4 et n sont tels que définis dans la description. L'invention concerne en outre des compositions pharmaceutiques comprenant de tels composés et sels, et des procédés et des utilisations de ces composés, sels et compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer, chez un sujet qui le nécessite.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3225045A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | HER2 MUTATION INHIBITORS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ELLIS,%20BRYAN%20DANIEL&rft.date=2022-12-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3225045A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |